ADA 2021: Recommendations From Dr. Silvio Inzucchi
Sunday, June 27, 2021; 2:15 PM–3:45 PM EST
Theme Area: Clinical Diabetes/Therapeutics
Symposium Efficacy and Safety of Dapagliflozin in Patients with and without Type 2 Diabetes Hospitalized with COVID-19—Results from the DARE-19 Global Randomized Controlled Trial (Includes Live Video Question and Answer Period). Chair, JB Green
Rationale, Design, and Baseline Characteristics of Patients in the DARE-19 Trial. MN Kosiborod
Efficacy Outcomes in Patients with and without Type 2 Diabetes. O Berwanger
Safety Outcomes in Patients with and without Type 2 Diabetes. S Verma
Clinical Implications of the DARE-19 Trial. MN Kosiborod
Independent Commentary. CSP Lam
Monday, June 28, 2021; 8:00 AM–10:00 AM EST
Theme Area: Clinical Diabetes/Therapeutics
Symposium Is Continuous Glucose Monitoring (CGM) an Effective Diabetes Management Tool in Primary Care? Co-Chairs, RM Bergenstal, E Wright, Jr
CGM Data Automatically Integrated into the Electronic Health Record—What Does It Take? AB Criego
Successful Use of CGM in Primary Care Depends on Patient Support and Workflow—Lessons from the Mobile Study. TW Martens
Can CGM Guide Effective and Sustainable Dietary Changes in the Primary Care Setting? D Gershenoff
Can CGM Combined with a Smart Pen Improve Insulin Management in Primary Care? D Isaacs
Could CGM Guided Clinical Decision-Making Be Effective in Primary Care? R Nimri
Monday, June 28, 2021; 4:30 PM–6:55 PM EST
Theme Area: Clinical Diabetes/Therapeutics
Symposium Results of the Glycemia Reduction Approaches in Diabetes—A Comparative Effectiveness (GRADE) Study (Includes Live Video Question and Answer Period). Co-Chairs, HC Gerstein, J Rosenstock
Rationale and Study Design. DM Nathan
Baseline Characteristics. M Tiktin
Conduct, Retention, and Adherence. H Krause-Steinrauf
Primary Outcome—Metabolic Results. JM Lachin
Microvascular Outcomes. DJ Wexler
Cardiovascular Outcomes and Mortality. JB Buse
Side Effects, Adverse Events, and Safety. ME Larkin
Summary/Conclusions. SE Kahn
Independent Commentary. DR Matthews
Tuesday, June 29, 2021; 8:00 AM–9:30 AM EST
Theme Area: Clinical Diabetes/Therapeutics
Symposium Next Chapter in Incretin-Based Therapies—Tirzepatide, a Novel Dual GIP/GLP-1 Receptor Agonist—Results from the First Phase 3 SURPASS Clinical Trials (Includes Live Video Question and Answer Period). Chair, AYY Cheng
Introduction. DJ Drucker
SURPASS-1—A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses vs. Placebo in Patients with Type 2 Diabetes Inadequately Controlled with Diet and Exercise Alone. CH Wysham, MD
SURPASS-2—A Phase 3, Randomized, Open-Label Trial Comparing the Efficacy and Safety of Tirzepatide vs. Semaglutide Once Weekly as Add-On Therapy to Metformin in Patients with Type 2 Diabetes. JP Frias
SURPASS-3—A Randomized, Phase 3, Open-Label Trial Comparing the Efficacy and Safety of Tirzepatide vs. Titrated Insulin Degludec in Patients with Type 2 Diabetes as Add-On to Metformin with or without SGLT2 Inhibitors. F Giorgino
SURPASS-5—A Randomized, Phase 3, Double-Blind Trial Comparing the Effect of the Addition of Tirzepatide vs. Placebo in Patients with Type 2 Diabetes Inadequately Controlled on Insulin Glargine with or without Metformin. M Welch
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles: